# Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

> **NCT01969838** · PHASE3 · COMPLETED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 432 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Momelotinib
- **DRUG:** Ruxolitinib
- **DRUG:** Placebo to match momelotinib
- **DRUG:** Placebo to match ruxolitinib

## Key facts

- **NCT ID:** NCT01969838
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-06
- **Primary completion:** 2016-09-12
- **Final completion:** 2019-05-02
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01969838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01969838, "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01969838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*